Last reviewed · How we verify

NCT03157726: ERP

Transurethral Plasmakinetic Enucleation of Prostate Versus Transurethral Resection of Prostate

Status unknown NA Last updated 3 March 2020
What this trial tests

NA trial testing Transurethral plasmakinetic enucleation of prostate in Benign Prostatic Hyperplasia in 294 participants. Status unknown.

Timeline
11 October 2017
Primary endpoint
6 June 2020
1 June 2021

Quick facts

Lead sponsorZhujiang Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment294
Start date11 October 2017
Primary completion6 June 2020
Estimated completion1 June 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Zhujiang Hospital

Who can join

Adults 50 to 80, male only, with Benign Prostatic Hyperplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a multicentric randomized control trial with 4-year follow-up comparing perioperative and postoperative outcomes for transurethral plasmakinetic enucleation of prostate(TUKEP) and transurethral resection of prostate(TURP). The investigators recruit patient with benign prostatic hyperplasia(BPH) as the object of study. TURP is set as control group . Meanwhile TUKEP is set as test group. Six affiliated hospitals will participate in this study. Through analyzing the perioperative and postoperative data between TUKEP group and TURP group, The investigators purpose demonstrating superiority of safety, efficacy and economic benefit in TUKEP group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Benign Prostatic Hyperplasia

Currently open trials in the same condition.

Other Zhujiang Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03157726.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing